SELECT: The selenium and vitamin E cancer prevention trial

Eric A. Klein, Ian M. Thompson, Scott M. Lippman, Phyllis J. Goodman, Demetrius Albanes, Philip R. Taylor, Charles Coltman

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Purpose: Growing evidence suggests that both selenium and vitamin E may reduce the risk of prostate cancer. SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiologic evidence regarding chemoprevention with selenium and vitamin E were reviewed. Secondary analyses from randomized trials of both agents were included in the analysis. Data from these analyses as well as evidence from the Prostate Cancer Prevention Trial were used to develop the schema of SELECT. Results: Preclinical, epidemiologic, and Phase III data suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial and the rapid accrual of SELECT during its first year demonstrate the interest and dedication of healthy men to long-term studies of cancer prevention. A total of 32,400 men are planned to be randomized in SELECT. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.

Original languageEnglish (US)
Pages (from-to)59-65
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume21
Issue number1
DOIs
StatePublished - Jan 2003

Fingerprint

Selenium
Vitamin E
Prostatic Neoplasms
Neoplasms
Chemoprevention
Anniversaries and Special Events
Double-Blind Method

Keywords

  • Chemoprevention
  • Prostate cancer
  • Selenium
  • Vitamin E

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Klein, E. A., Thompson, I. M., Lippman, S. M., Goodman, P. J., Albanes, D., Taylor, P. R., & Coltman, C. (2003). SELECT: The selenium and vitamin E cancer prevention trial. Urologic Oncology: Seminars and Original Investigations, 21(1), 59-65. https://doi.org/10.1016/S1078-1439(02)00301-0

SELECT : The selenium and vitamin E cancer prevention trial. / Klein, Eric A.; Thompson, Ian M.; Lippman, Scott M.; Goodman, Phyllis J.; Albanes, Demetrius; Taylor, Philip R.; Coltman, Charles.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 21, No. 1, 01.2003, p. 59-65.

Research output: Contribution to journalArticle

Klein, EA, Thompson, IM, Lippman, SM, Goodman, PJ, Albanes, D, Taylor, PR & Coltman, C 2003, 'SELECT: The selenium and vitamin E cancer prevention trial', Urologic Oncology: Seminars and Original Investigations, vol. 21, no. 1, pp. 59-65. https://doi.org/10.1016/S1078-1439(02)00301-0
Klein, Eric A. ; Thompson, Ian M. ; Lippman, Scott M. ; Goodman, Phyllis J. ; Albanes, Demetrius ; Taylor, Philip R. ; Coltman, Charles. / SELECT : The selenium and vitamin E cancer prevention trial. In: Urologic Oncology: Seminars and Original Investigations. 2003 ; Vol. 21, No. 1. pp. 59-65.
@article{0add3140332d45a1a675a0d717534553,
title = "SELECT: The selenium and vitamin E cancer prevention trial",
abstract = "Purpose: Growing evidence suggests that both selenium and vitamin E may reduce the risk of prostate cancer. SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiologic evidence regarding chemoprevention with selenium and vitamin E were reviewed. Secondary analyses from randomized trials of both agents were included in the analysis. Data from these analyses as well as evidence from the Prostate Cancer Prevention Trial were used to develop the schema of SELECT. Results: Preclinical, epidemiologic, and Phase III data suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial and the rapid accrual of SELECT during its first year demonstrate the interest and dedication of healthy men to long-term studies of cancer prevention. A total of 32,400 men are planned to be randomized in SELECT. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.",
keywords = "Chemoprevention, Prostate cancer, Selenium, Vitamin E",
author = "Klein, {Eric A.} and Thompson, {Ian M.} and Lippman, {Scott M.} and Goodman, {Phyllis J.} and Demetrius Albanes and Taylor, {Philip R.} and Charles Coltman",
year = "2003",
month = "1",
doi = "10.1016/S1078-1439(02)00301-0",
language = "English (US)",
volume = "21",
pages = "59--65",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - SELECT

T2 - The selenium and vitamin E cancer prevention trial

AU - Klein, Eric A.

AU - Thompson, Ian M.

AU - Lippman, Scott M.

AU - Goodman, Phyllis J.

AU - Albanes, Demetrius

AU - Taylor, Philip R.

AU - Coltman, Charles

PY - 2003/1

Y1 - 2003/1

N2 - Purpose: Growing evidence suggests that both selenium and vitamin E may reduce the risk of prostate cancer. SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiologic evidence regarding chemoprevention with selenium and vitamin E were reviewed. Secondary analyses from randomized trials of both agents were included in the analysis. Data from these analyses as well as evidence from the Prostate Cancer Prevention Trial were used to develop the schema of SELECT. Results: Preclinical, epidemiologic, and Phase III data suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial and the rapid accrual of SELECT during its first year demonstrate the interest and dedication of healthy men to long-term studies of cancer prevention. A total of 32,400 men are planned to be randomized in SELECT. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.

AB - Purpose: Growing evidence suggests that both selenium and vitamin E may reduce the risk of prostate cancer. SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiologic evidence regarding chemoprevention with selenium and vitamin E were reviewed. Secondary analyses from randomized trials of both agents were included in the analysis. Data from these analyses as well as evidence from the Prostate Cancer Prevention Trial were used to develop the schema of SELECT. Results: Preclinical, epidemiologic, and Phase III data suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial and the rapid accrual of SELECT during its first year demonstrate the interest and dedication of healthy men to long-term studies of cancer prevention. A total of 32,400 men are planned to be randomized in SELECT. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.

KW - Chemoprevention

KW - Prostate cancer

KW - Selenium

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=0141922731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141922731&partnerID=8YFLogxK

U2 - 10.1016/S1078-1439(02)00301-0

DO - 10.1016/S1078-1439(02)00301-0

M3 - Article

C2 - 12684129

AN - SCOPUS:0141922731

VL - 21

SP - 59

EP - 65

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 1

ER -